| Similar Articles |
|---|
 |
The Motley Fool
October 24, 2008
Brian Orelli |
Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell.   |
The Motley Fool
April 24, 2008
Brian Orelli |
Illumina Ignites This biochip maker is on fire. |
The Motley Fool
October 25, 2007
Brian Orelli |
Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter. |
The Motley Fool
February 6, 2008
Brian Orelli |
Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward? |
The Motley Fool
January 28, 2005
Karl Thiel |
Affymetrix Raking in the Chips The life sciences research chip maker is enjoying green pastures in the gene business. The company announced fourth-quarter revenues and profits that handily beat consensus expectations, and then gave an upbeat view of 2005. |
The Motley Fool
April 25, 2008
Brian Orelli |
Affymetrix Learns About Inertia Slower sales of its older chips drag down growth. |
The Motley Fool
January 11, 2008
Brian Orelli |
Biochip Packaging: Some Settling May Occur Biochip maker Illumina settles its disputes about patents with Affymetrix. |
The Motley Fool
April 24, 2006
John Bluis |
Affymetrix Gets Chipped Again The woes continue for Affymetrix, the leading provider of high-density microarray products. Investors must decide if this is a management issue -- as indeed it appears to be. |
The Motley Fool
August 7, 2006
Stephen D. Simpson |
Affymetrix: Price Always Matters Affymetrix has legit technology, but that doesn't mean it has infinite value for investors. |
The Motley Fool
July 23, 2011 |
Affymetrix Earnings Preview Affymetrix will unveil its latest earnings on Wednesday, July 27. |
The Motley Fool
November 12, 2008
Brian Orelli |
Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash. |
The Motley Fool
January 31, 2006
John Bluis |
Affymetrix: Far, Far Array Investors who enjoy companies that are consistent with guidance may have some interest in this company that provides tools for use in genomics-related research. Unfortunately, this year the consistency was in reporting disappointing results. |
The Motley Fool
July 26, 2007
Brian Orelli |
Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit. |
The Motley Fool
January 30, 2007
Brian Lawler |
Schering-Plough Pushes Ahead The drugmaker successfully continues with its multi-year turnaround plan. Investors would be smart to take a look at this pharmaceutical turnaround stock before it starts to get noticed again. |
The Motley Fool
July 25, 2007
Brian Orelli |
Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row. |
InternetNews
June 8, 2006
Paul Shread |
TI Hikes Guidance Texas Instruments capped a dramatic turnaround in the stock market Thursday with better than expected earnings and sales guidance... Stocks staged a dramatic turnaround Thursday... Alcatel and Lucent lost ground... etc. |
The Motley Fool
August 11, 2010
Seth Jayson |
Marginal Performance at Affymetrix Here's the current margin snapshot for Affymetrix and some of its sector and industry peers, and direct competitors. |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out. |
The Motley Fool
October 28, 2009
Brian Orelli |
Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably. |
The Motley Fool
July 24, 2008
Brian Orelli |
Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth. |
The Motley Fool
July 22, 2005
Stephen D. Simpson |
Big Miss Afflicts Affymetrix Gee-whiz technology doesn't always mean gee-whiz growth. While the facilitator of genetics research and drug development enjoyed has recovered significantly from its lows, long-term investors saw another market thrashing on a disappointing outlook. |
The Motley Fool
October 24, 2007
Brian Orelli |
Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down. |
The Motley Fool
October 24, 2005
Stephen D. Simpson |
Vytorin Lifts Schering-Plough While the pharma is now officially in a turnaround phase, the news may already be baked into the stock. |
The Motley Fool
October 22, 2008
Jim Mueller |
Illuminating Illumina Did the DNA analysis equipment maker miss, meet, or beat expectations? Well, it's complicated. |
The Motley Fool
April 27, 2007
Brian Orelli |
Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note. |
The Motley Fool
March 19, 2007
David Meier |
The Kirkland Conundrum The turnaround effort continues at the home decor retailer. Investors, take note. |
The Motley Fool
August 30, 2010
Seth Jayson |
Is Affymetrix Growing or Slowing? Is Affymetrix sending any warning signs? Take a look at its accounts receivable and days sales outstanding to find out. |
Bio-IT World
July 2005
Johan Bostrom |
Affymetrix to Acquire ParAllele The companies have been working together for the past two years, with Affymetrix using ParAllele's assay technology with the Affymetrix GeneChip technology. Affymetrix expects to strengthen its assay R&D capabilities and add knowledge in specific assay capabilities through the acquisition. |
The Motley Fool
September 28, 2005
Stephen D. Simpson |
Affymetrix Stumbles Again Though the company was one of the only genomics plays to escape the bubble with a real business and a solid market cap, Affymetrix's stock seemed poised to take a serious hit Wednesday for the second time in about three months. |
The Motley Fool
February 8, 2010
Brian Orelli |
An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement. |
The Motley Fool
December 9, 2010
Seth Jayson |
Affymetrix Passes This Key Test By considering the trends in accounts receivable and days sales outstanding we can get a window into Affymetrix's future. |
The Motley Fool
April 6, 2006
Stephen D. Simpson |
Has Pier 1's Ship Come In? Investors seem to think that new steps will turn this business around. But March comps make it clear that there's still more work to do. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Not Banking Yet on Fifth Third When considering an investment in this bank, remember that a turnaround story isn't a turnaround until it actually turns around. |
Wired
June 2000
Brian Alexander |
Biopoly Money Patents and strong-arm tactics are helping make Affymetrix the Intel of biochips. Along the way, Affy wants to turn DNA into a proprietary system. |
The Motley Fool
April 22, 2009
Brian Orelli |
Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away. |
